Compare Global E Online Ltd (GLBE) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global E Online Ltd vs BIO-TECHNE Corp — how do they compare? Global E Online Ltd trades at $39.81 (market cap $6.54B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Global E Online Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global E Online Ltd for 21 Days and BIO-TECHNE Corp for 63 Days on average.
| GLBE | TECH | |
|---|---|---|
Market Cap | $6.54B | $11.37B |
Volume | 1,011,873 | 3,153,511 |
Sector | Consumer Cyclical | Health |
52-Week High | $42.36 | $72.61 |
52-Week Low | $27.54 | $43.31 |
Typical Hold Time | 21 Days | 63 Days |
Enterprise Value | $6.04B | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLBE trades at $38.96, up 0.67% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating EPS estimates, and raised its full-year outlook, with revenue growth of 39% year-over-year. Recent news includes the appointment of Tomer Gold as Chief Revenue Officer and significant insider selling by executives.
The outlook is positive with robust analyst support—93% buy ratings and a $48.86 consensus price target implying 25% upside. Key risks include insider selling pressure and execution challenges in maintaining high growth. Earnings growth and margin expansion remain primary catalysts for stock appreciation.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
